Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MOF Budget Examiner Questions Price Maintenance Premium, Says Its Impact Amounts to Over 253 Billion Yen in FY2017
September 12, 2017
- MHLW to Draft GL on Use of Real World Data in Application Filings to Promote Development of Drugs for Rare Diseases
September 12, 2017
- Kyorin’s Dimethyl Sulfoxide Gets Orphan Status in Japan
September 11, 2017
- MHLW Panel Backs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med and More
September 11, 2017
- Opdivo Clears MHLW Panel for 3rd Line Use in Gastric Cancer, Keytruda to Lose Sakigake Status
September 8, 2017
- Social Security Council Begins Discussion on Basic Policy for FY2018 Reimbursement Reform
September 8, 2017
- MEXT’s FY2018 Budget Request to Include Funding to Build Biobank Network
September 8, 2017
- MHLW Sets Out Plan to Ease Export Ban for Plasma Fraction Products
September 7, 2017
- MHLW Working Group to Draw Up Elderly Polypharmacy Guidelines in 2 Stages
September 4, 2017
- Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients
September 4, 2017
- Programs Funded by MA Holder or Its Subsidiaries Subject to Regulations under Clinical Research Law
September 1, 2017
- MHLW to Form Study Group to Address Leftover Vial Drug Issue, Weighs Multi-Dose Vials
August 30, 2017
- MHLW Panels Eye Cognitive Behavioral Therapy Approach for Post-HPV Vaccine Symptoms
August 29, 2017
- New Minister Has Hopes for Pharma Industry in Both Medical and Economic Fronts, Wants to Balance Innovation and Cost
August 29, 2017
- MHLW Predicts 4% Reduction in Flu Vaccine Production in FY2017, Will Take Steps to Prevent Shortage
August 29, 2017
- MHLW OKs Add’l Indications for Revolade, Actemra and More
August 28, 2017
- Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8
August 28, 2017
- MHLW Health Policy Bureau to Initiate a New Project to Increase Understanding of Biosimilars; FY2018 Budget Request
August 28, 2017
- MHLW Pharmaceutical Safety Bureau Seeks 10.3 Billion Yen in FY2018 Budget; Includes Funding for 6 Add’l Personnel at PMDA
August 28, 2017
- MHLW Working Group to Kick Off Discussions on Guidelines to Address Elderly Polypharmacy
August 25, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…